PL3502105T3 - Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie - Google Patents
Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanieInfo
- Publication number
- PL3502105T3 PL3502105T3 PL17855006T PL17855006T PL3502105T3 PL 3502105 T3 PL3502105 T3 PL 3502105T3 PL 17855006 T PL17855006 T PL 17855006T PL 17855006 T PL17855006 T PL 17855006T PL 3502105 T3 PL3502105 T3 PL 3502105T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- pharmaceutical composition
- composition containing
- kinase inhibitor
- method therefor
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610866253 | 2016-09-29 | ||
| PCT/CN2017/104506 WO2018059556A1 (zh) | 2016-09-29 | 2017-09-29 | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 |
| EP17855006.7A EP3502105B8 (en) | 2016-09-29 | 2017-09-29 | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3502105T3 true PL3502105T3 (pl) | 2022-07-11 |
Family
ID=61763329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17855006T PL3502105T3 (pl) | 2016-09-29 | 2017-09-29 | Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11053224B2 (pl) |
| EP (1) | EP3502105B8 (pl) |
| JP (2) | JP7253491B2 (pl) |
| KR (1) | KR102289684B1 (pl) |
| CN (1) | CN108884080B (pl) |
| AU (1) | AU2017336889B2 (pl) |
| BR (1) | BR112019006023A2 (pl) |
| CA (1) | CA3035124A1 (pl) |
| EA (1) | EA201990688A1 (pl) |
| ES (1) | ES2914294T3 (pl) |
| HK (1) | HK1257194A1 (pl) |
| IL (1) | IL265266B1 (pl) |
| MY (1) | MY194364A (pl) |
| PH (1) | PH12019500681A1 (pl) |
| PL (1) | PL3502105T3 (pl) |
| SG (1) | SG11201901962QA (pl) |
| TW (1) | TWI647224B (pl) |
| WO (1) | WO2018059556A1 (pl) |
| ZA (1) | ZA201901717B (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY194364A (en) * | 2016-09-29 | 2022-11-29 | Equinox Sciences Llc | Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use Thereof |
| WO2021195163A1 (en) | 2020-03-25 | 2021-09-30 | Ocular Therapeutix, Inc. | Ocular implant containing a tyrosine kinase inhibitor |
| BR112023018649A2 (pt) * | 2021-03-16 | 2023-10-10 | Hk Inno N Corp | Forma cristalina e método para preparar uma forma cristalina |
| JP7138982B1 (ja) * | 2021-09-24 | 2022-09-20 | 東海物産株式会社 | アンセリンの結晶及びその製造方法 |
| WO2023173088A1 (en) | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | Method of preventing age-related macular degeneration by administering an ocular drug delivery insert |
| WO2023173093A1 (en) | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | Continuous dosing regimen for treatment of a condition of the eye |
| TW202345804A (zh) | 2022-03-11 | 2023-12-01 | 美商視點製藥有限公司 | 治療濕性老年黃斑部病變(Wet Age-related Macular Degeneration)之方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1434774A1 (en) * | 2001-10-10 | 2004-07-07 | Sugen, Inc. | 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
| CN101553482B (zh) * | 2006-09-15 | 2013-11-20 | 艾科睿制药公司 | 激酶抑制剂化合物 |
| WO2008134909A1 (de) * | 2007-05-07 | 2008-11-13 | Baumer Electric Ag | Akustischer wandler |
| US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| CA2720943A1 (en) * | 2008-04-16 | 2009-10-22 | Natco Pharma Limited | Novel polymorphic forms of sunitinib base |
| CN102066362B (zh) | 2008-05-23 | 2014-07-30 | 上海医药工业研究院 | 二氢吲哚酮衍生物 |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| EP2264027A1 (en) | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技（上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
| MY194364A (en) * | 2016-09-29 | 2022-11-29 | Equinox Sciences Llc | Polymorphic Forms of Kinase Inhibitor Compound, Pharmaceutical Composition Containing Same, Preparation Method Therefor and use Thereof |
-
2017
- 2017-09-29 MY MYPI2019000596A patent/MY194364A/en unknown
- 2017-09-29 AU AU2017336889A patent/AU2017336889B2/en active Active
- 2017-09-29 EA EA201990688A patent/EA201990688A1/ru unknown
- 2017-09-29 KR KR1020197008752A patent/KR102289684B1/ko active IP Right Grant
- 2017-09-29 CN CN201780008042.1A patent/CN108884080B/zh active Active
- 2017-09-29 ES ES17855006T patent/ES2914294T3/es active Active
- 2017-09-29 TW TW106133830A patent/TWI647224B/zh active
- 2017-09-29 BR BR112019006023A patent/BR112019006023A2/pt unknown
- 2017-09-29 WO PCT/CN2017/104506 patent/WO2018059556A1/zh unknown
- 2017-09-29 PL PL17855006T patent/PL3502105T3/pl unknown
- 2017-09-29 EP EP17855006.7A patent/EP3502105B8/en active Active
- 2017-09-29 US US16/338,357 patent/US11053224B2/en active Active
- 2017-09-29 IL IL265266A patent/IL265266B1/en unknown
- 2017-09-29 JP JP2019538551A patent/JP7253491B2/ja active Active
- 2017-09-29 SG SG11201901962QA patent/SG11201901962QA/en unknown
- 2017-09-29 CA CA3035124A patent/CA3035124A1/en active Pending
-
2018
- 2018-12-18 HK HK18116171.7A patent/HK1257194A1/zh unknown
-
2019
- 2019-03-19 ZA ZA201901717A patent/ZA201901717B/en unknown
- 2019-03-28 PH PH12019500681A patent/PH12019500681A1/en unknown
-
2021
- 2021-06-15 US US17/348,482 patent/US20220356173A1/en active Pending
-
2023
- 2023-03-28 JP JP2023052465A patent/JP2023082086A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019529568A (ja) | 2019-10-17 |
| CN108884080B (zh) | 2020-10-27 |
| KR102289684B1 (ko) | 2021-08-12 |
| TW201815785A (zh) | 2018-05-01 |
| CA3035124A1 (en) | 2018-04-05 |
| ES2914294T3 (es) | 2022-06-08 |
| MY194364A (en) | 2022-11-29 |
| US20190233403A1 (en) | 2019-08-01 |
| WO2018059556A1 (zh) | 2018-04-05 |
| HK1257194A1 (zh) | 2019-10-18 |
| EP3502105B1 (en) | 2022-03-30 |
| EP3502105B8 (en) | 2022-06-01 |
| JP7253491B2 (ja) | 2023-04-06 |
| EP3502105A1 (en) | 2019-06-26 |
| IL265266A (en) | 2019-05-30 |
| BR112019006023A2 (pt) | 2019-06-18 |
| EP3502105A4 (en) | 2020-04-15 |
| EA201990688A1 (ru) | 2019-08-30 |
| US11053224B2 (en) | 2021-07-06 |
| KR20190039823A (ko) | 2019-04-15 |
| AU2017336889B2 (en) | 2021-11-25 |
| JP2023082086A (ja) | 2023-06-13 |
| IL265266B1 (en) | 2024-04-01 |
| ZA201901717B (en) | 2019-11-27 |
| AU2017336889A1 (en) | 2019-04-11 |
| SG11201901962QA (en) | 2019-04-29 |
| US20220356173A1 (en) | 2022-11-10 |
| TWI647224B (zh) | 2019-01-11 |
| CN108884080A (zh) | 2018-11-23 |
| PH12019500681A1 (en) | 2019-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201901717B (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| IL254736B (en) | Imidazole [1,2-c]pyrimidine derivative compounds, 1LSD inhibitors, pharmaceutical compound comprising them and use for cancer treatment | |
| IL282801A (en) | Compounds, pharmaceutical compounds, and methods of making compounds and using them as ATR kinase inhibitors | |
| EP3672973A4 (en) | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | |
| SG11202011513RA (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| HK1244704A1 (zh) | 一種含有jak激酶抑制劑或其可藥用鹽的藥物組合物 | |
| HK1232229A1 (zh) | '- '-硫代核苷的新型化合物及其製備方法、藥物組合物和應用 | |
| HK1253537A1 (zh) | 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法 | |
| EP3412669A4 (en) | TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| HK1258996A1 (zh) | 新型fyn激酶抑制劑的方法、組合物以及用途 | |
| EP3376870A4 (en) | PROCESS FOR PREPARING KINASE INHIBITORS AND INTERMEDIATES THEREOF | |
| ZA201805600B (en) | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | |
| IL264593A (en) | Medicinal preparations containing akt protein kinase inhibitors | |
| EP3697791A4 (en) | HETEROCYCLIC COMPOUNDS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| HK1217303A1 (zh) | 種治療白血病的藥物組合物及其製備方法 | |
| EP3196194A4 (en) | Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound | |
| EP3314001A4 (en) | METHODS AND COMPOSITIONS FOR THE PREPARATION OF EPPHEDIN AND RELATED ALKALOID COMPOUNDS | |
| EP3717475A4 (en) | KINASEINHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | |
| PT3398946T (pt) | Sal de derivado de morfolina e a sua forma cristalina, bem como método de preparação, composição farmacêutica e a sua utilização | |
| EP3216791A4 (en) | Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof | |
| EP3707127A4 (en) | COMPOUNDS FOR INHIBITION OF LY6K AND METHOD OF USING THEREOF | |
| IL247645A0 (en) | Preparations of seleno-organic compounds and methods of using them | |
| IL275667A (en) | A compound capable of application as a growth inhibitor, its preparation methods and its use | |
| EP3681492A4 (en) | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AS INHIBITORS OF RAN-GTPASE |